BiondVax Pharmaceuticals
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hadassah Ein Kerem Campus Jerusalem Biop...Phone Number
+972 89302529Website
www.biondvax.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BiondVax Pharmaceuticals
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. . With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.Explore more
BiondVax Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BiondVax Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on BiondVax Pharmaceuticals recently announced quarterly report
Check if BiondVax Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when BiondVax Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if BiondVax Pharmaceuticals had a recent Job posting/layoffs
BiondVax Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if BiondVax Pharmaceuticals is spiking on competitors!
Funding: Get notified immidiatlly once BiondVax Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BiondVax Pharmaceuticals
Recommended Actions
Find VP level buyers at BiondVax Pharmaceuticals
Find 3 more new buyers
Company Profile Activity
Activity Insights
BiondVax Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BiondVax Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BiondVax Pharmaceuticals.
BiondVax Pharmaceuticals financials insights
Gather financial insights about BiondVax Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Debt
$22.3M
BiondVax Pharmaceuticals Tech Stack
A closer look at the technologies used by BiondVax Pharmaceuticals
Most Recent Scoops
Lateral Move
Executive Move
New Hire
Executive Move
Lateral Move
Executive Move
New Hire
Executive Move
BiondVax Pharmaceuticals News & Media
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
JERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance.BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis
JERUSALEM, June 05, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announces that as part of its ongoing broad-based collaboration with the Max Planck Society and the University Medical Center Gottingen (UMG), it has signed an exclusive worldwide license agreemenBiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
JERUSALEM, April 17, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today published its full-year financial results for the year ended December 31, 2022, and provided a business update. At the same time, the Company filed its Annual Report on Form 10-K with the SecuritBiondVax to Present at BIO-Europe Spring
JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring toge
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BiondVax Pharmaceuticals
Sign Up For FreeTo access detailed company insights
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. . With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified an... Read More
